Patents by Inventor Gary L. Stetler
Gary L. Stetler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6291662Abstract: A synthetic DNA sequence and its genetic equivalents are disclosed which sequences are capable, when used in a recombinant DNA method, of directing production of a serine protease inibitor protein. Recombinant DNA methods for the production of serine protease inhibitor proteins are also disclosed. These methods incorporate either the synthetic DNA sequence of the present invention or natural DNA sequences isolated from human cDNA or genomic libraries.Type: GrantFiled: September 22, 1998Date of Patent: September 18, 2001Assignee: Amgen Inc.Inventors: Pradip K. Bandyopadhyay, Stephen P. Eisenberg, Gary L. Stetler, Robert C. Thompson
-
Patent number: 6274331Abstract: A functional linker for a polypeptide in which two alpha or beta globin-like domains are genetically fused is determined by screening a library of genetically fused polypeptides, in which the linker region is varied, for the ability to participate in the formation of hemoglobin-like protein, as measured by the protein's response to carbon monoxide. In a preferred embodiment, cells expressing the protein turn red as a result of carbon monoxide pressure.Type: GrantFiled: May 19, 1995Date of Patent: August 14, 2001Assignee: Somatogen, Inc.Inventors: Douglas L. Looker, Gary L. Stetler
-
Patent number: 6184356Abstract: DNA molecules which encode pseudodimeric globin-like polypeptides with an asymmetric cysteine mutation suitable for crosslinking two tetramers, or which encode pseudooligomeric globin-like polypeptides comprising four or more globin-like domains, are useful in the preparation of multimeric hemoglobin-like proteins.Type: GrantFiled: April 13, 1998Date of Patent: February 6, 2001Assignee: Baxter Biotech Technology SarlInventors: David C. Anderson, Antony J. Mathews, Gary L. Stetler
-
Patent number: 6132990Abstract: A synthetic DNA sequence and its genetic equivalents are disclosed which sequences are capable, when used in a recombinant DNA method, of directing production of a serine protease inibitor protein. Recombinant DNA methods for the production of serine protease inhibitor proteins are also disclosed. These methods incorporate either the synthetic DNA sequence of the present invention or natural DNA sequences isolated from human cDNA or genomic libraries.In addition, a single polypeptide chain protein is disclosed which is capable of inhibiting chymotrypsin and elastase but not trypsin. In one embodiment, this protein is a shortened from (single domain) of the protein produced by the method described herein.Type: GrantFiled: June 7, 1991Date of Patent: October 17, 2000Assignee: Amgen Boulder Inc.Inventors: Pradip K. Bandyopadhyay, Stephen P. Eisenberg, Gary L. Stetler, Robert C. Thompson
-
Patent number: 5871956Abstract: A synthetic DNA sequence and its genetic equivalents are disclosed which sequences are capable, when used in a recombinant DNA method, of directing production of a serine protease inibitor protein. Recombinant DNA methods for the production of serine protease inhibitor proteins are also disclosed. These methods incorporate either the synthetic DNA sequence of the present invention or natural DNA sequences isolated from human cDNA or genomic libraries.Type: GrantFiled: July 22, 1994Date of Patent: February 16, 1999Assignee: Amgen Inc.Inventors: Pradip K. Bandyopadhyay, Stephen P. Eisenberg, Gary L. Stetler, Robert C. Thompson
-
Patent number: 5844089Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.Type: GrantFiled: May 25, 1995Date of Patent: December 1, 1998Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Douglas L. Looker, Mary S. Rosendahl, Gary L. Stetler, Michael Wagenbach, David C. Anderson, Antony James Mathews, Kiyoshi Nagai
-
Patent number: 5844088Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.We further describe the production of tetrameric human hemoglobin and di-alpha/beta.sub.2 hemoglobin in the yeast Saccharomyces cerevisiae. The synthesis of the protein is directed by a synthetic promotor consisting of two functional parts, an upstream activator sequence (UAS) that confers inducible transcription by galactose from a consensus yeast transcriptional initiation site.Type: GrantFiled: May 19, 1995Date of Patent: December 1, 1998Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Douglas L. Looker, Mary S. Rosendahl, Gary L. Stetler, Michael Wagenbach, David C. Anderson, Antony James Mathews, Kiyoshi Nagai
-
Patent number: 5798227Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.We further describe the production of tetrameric human hemoglobin and di-alpha/beta.sub.2 hemoglobin in the yeast Saccharomyces cerevisiae. The synthesis of the protein is directed by a synthetic promotor consisting of two functional parts, an upstream activator sequence (UAS) that confers inducible transcription by galactose from a consensus yeast transcriptional initiation site.Type: GrantFiled: May 19, 1995Date of Patent: August 25, 1998Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Douglas L. Looker, Gary L. Stetler, Michael Wagenbach
-
Patent number: 5744329Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.Type: GrantFiled: May 19, 1995Date of Patent: April 28, 1998Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Douglas L. Looker, Mary S. Rosendahl, Gary L. Stetler, Michael Wagenbach, David C. Anderson, Antony James Mathews, Kiyoshi Nagai
-
Patent number: 5739011Abstract: DNA molecules which encode pseudodimeric globin-like polypeptides with an asymmetric cysteine mutation suitable for crosslinking two tetramers, or which encode pseudooligomeric globin-like polypeptides comprising four or more globin-like domains, are useful in the preparation of multimeric hemoglobin-like proteins.Type: GrantFiled: May 31, 1995Date of Patent: April 14, 1998Assignee: Somatogen, Inc.Inventors: David C. Anderson, Antony James Mathews, Gary L. Stetler
-
Patent number: 5717058Abstract: The present invention relates to regulators of cellular gene transcription, particularly inhibitors of cellular gene transactivating factors and in particular to inhibition of gene transcription in a viral host cell that is subject to regulation by proteins or factors that originate from a virus as well as conjugates or fusion products of the inhibitors and internalization molecules, pharmaceutical compositions that can be used to alleviate or prevent the manifestation of disease states that are the result of unregulated DNA transcription as a result of transactivation, methods of treating diseases that are caused or exacerbated by the presence of transactivating factors, and regulated gene therapy to achieve long term drug delivery of the inhibitors of the present invention. This invention can be applied both to cells with genetic abnormalities or to cells infected with a virus. Preferably, at least one protein of the protein-protein interactions is a transactivating factor.Type: GrantFiled: February 18, 1994Date of Patent: February 10, 1998Assignee: Somatogen, Inc.Inventors: Maura-Ann H. Matthews, Gary L. Stetler, Spencer J. Anthony-Cahill, David C. Anderson
-
Patent number: 5599907Abstract: Multimeric hemoglobin-like proteins are obtained by crosslinking cysteines of the component tetramers, or by genetically fusing globin-like domains of one tetramer with those of another, by means of an interdomain spacer sequence. Artificial cysteines are introduced selectively in a single globin-like domain per tetramer to control polymerization.Type: GrantFiled: May 9, 1994Date of Patent: February 4, 1997Assignee: Somatogen, Inc.Inventors: David C. Anderson, Antony J. Mathews, Gary L. Stetler